Advertisement
Critical Review| Volume 11, ISSUE 8, P701-709, August 2010

The Determination and Application of Fixed-Dose Analgesic Combinations for Treating Multimodal Pain

      Abstract

      When the pathophysiology of a medical condition is multimodal, ie, related to multiple physiological causes or mediated by multiple pathways, the optimal strategy can be to use a drug or a combination of drugs that contribute multiple mechanisms to the therapeutic endpoint. In such situations, a rational multimodal approach can also result in the fewest adverse effects. We discuss the quantitative analysis of multimodal action using the treatment of pain as a practical example and give examples of its application to some widely used analgesic drugs.

      Perspective

      This article reviews the medical relevance of the quantitative evaluation of drug combinations, using pain and combinations of analgesics as specific examples. Such measure can help clinicians who seek to maximize therapeutic effect while simultaneously minimizing adverse effects.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. American Geriatrics Society http://www.americangeriatrics.org/education/pharm_management.shtml (last accessed September 24, 2009)

        • Arnold L.M.
        Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.
        Pain Med. 2007; 2: S63-S74
        • Backonja M.
        • Glanzman R.L.
        Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials.
        Clin Ther. 2003; 25: 81-104
        • Berger A.
        • Dukes E.
        • McCarberg B.
        • Liss M.
        • Oster G.
        Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia.
        Clin Ther. 2003; 25: 2809-2821
        • Bennett R.
        (for the CAPSS-112 Study Group), Kamin M, Rosenthal N, Karim R: Efficacy and safety of a tramadol/acetaminophen combination (ULTRACET™) in the management of fibromyalgia related pain: A multicenter, outpatient, randomized, double-blind, placebo-controlled study.
        Arthritis Rheum. 2001; 44: S67
        • Bian D.
        • Ossipov M.H.
        • Ibrahim M.
        • Raffa R.B.
        • Tallarida R.J.
        • Malan T.P.
        • Lai J.
        • Porreca F.
        Loss of antiallodynic and antinociceptive spinal-supraspinal morphine synergy in nerve-injured rats: Restoration by MK-801 or dynorphin antiserum.
        Brain Res. 1999; 831: 55-63
        • Bolan E.A.
        • Tallarida R.J.
        • Pasternak G.
        Synergy between mu receptor subtypes: Evidence for functional interaction among mu receptor subtypes.
        J Pharmacol Exp Ther. 2002; 303: 557-562
        • Borenstein D.G.
        (for the CAPSS-112 Study Group), Kamin M, Rosenthal N, Karim R: Combination tramadol and acetaminophen (ULTRACET™) for the treatment of chronic lower back pain: A multicenter, outpatient, randomized, double-blind, placebo-controlled study.
        Arthritis Rheum. 2001; 44: S67
        • Briley M.
        • Moret C.
        Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors.
        CNS Spectrums. 2008; 13: 22-26
        • Casella G.
        • Berger R.L.
        Statistical Inference.
        Duxbury Press, Grove, CA2002 (pp 243)
        • Codd E.E.
        • Martinez R.P.
        • Molino L.
        • Rogers K.E.
        • Stone D.J.
        • Tallarida R.J.
        Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia.
        Pain. 2008; 134: 254-262
        • Dworkin R.H.
        • Backonja M.
        • Rowbotham M.C.
        • Allen R.R.
        • Argoff C.R.
        • Bennett G.J.
        • Bushnell M.C.
        • Farrar J.T.
        • Galer B.S.
        • Haythornthwaite J.A.
        • Hewitt D.J.
        • Loeser J.D.
        • Max M.B.
        • Saltarelli M.
        • Schmader K.E.
        • Stein C.
        • Thompson D.
        • Turk D.C.
        • Wallace M.S.
        • Watkins L.R.
        • Weinstein S.M.
        Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations.
        Arch Neurol. 2003; 60: 1524-1534
        • Fairbanks C.A.
        • Stone L.S.
        • Kitto K.F.
        • Nguyen H.O.
        • Posthumus I.J.
        • Wilcox G.L.
        Alpha2C-adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy.
        J Pharmacol Exp Ther. 2002; 300: 282-290
      2. FDA: Joint meeting of the Drug Safety and Risk Management Advisory Committee Nonprescription Drugs Advisory Committee and Anesthetic and Life Support Drugs Committee, Notice of Meeting Federal Register 74:28 April 24, 2009. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/E9-9380.pdf (last accessed September 24, 2009)

        • Field M.K.
        • Gonzalez M.I.
        • Tallarida R.J.
        • Singh L.
        Gabapentin and the NK1 antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
        J Pharmacol Exp Ther. 2002; 303: 730-735
        • Field M.J.
        • Cox P.J.
        • Stott E.
        • Melrose H.
        • Offord J.
        • Su T.-Z.
        • Bramwell S.
        • Corradini L.
        • England S.
        • Winks J.
        • Kinloch R.A.
        • Hendrich J.
        • Dolphin A.C.
        • Webb T.
        • Williams D.
        Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin.
        Proc Natl Acad Sci USA. 2006; 103: 17537-17542
        • Gajraj N.M.
        Pregabalin for pain management.
        Pain Practice. 2005; 5: 95-102
      3. Galer B.S. Dworkin R.H. A Clinical Guide to Neuropathic Pain. McGraw-Hill, Minneapolis, MN2000: 22-32
        • Galer B.S.
        • Jensen M.P.
        • Ma T.
        • Davies P.S.
        • Rowbotham M.C.
        The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale.
        Clin J Pain. 2002; 18: 297-301
        • Grabovsky Y.
        • Tallarida R.J.
        Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles.
        J Pharmacol Exp Ther. 2004; 310: 981-986
        • Hanna M.
        • O'Brien C.
        • Wilson M.C.
        Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.
        Eur J Pain. 2008; 12: 804-813
        • Hartrick C.T.
        Multimodal postoperative pain management.
        Am J Health Syst Pharm. 2004; 61: S4-S10
        • Horan P.
        • Tallarida R.J.
        • Haaseth R.C.
        • Matsunaga T.O.
        • Hruby V.J.
        • Porreca F.
        Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: Supra- and sub-additivity.
        Life Sci. 1992; 50: 1535-1541
      4. Irving G.A. Wallace M.S. Pain Management for the Practicing Physician. Churchill Livingstone, New York, NY1997: 9-16
        • Kalso E.
        • Edwards J.E.
        • Moore R.A.
        • McQuay H.J.
        Opioids in chronic non-cancer pain: Systematic review of efficacy and safety.
        Pain. 2004; 112: 372-380
        • Kalso E.
        • Simpson K.H.
        • Slappendel R.
        • Dejonckheere J.
        • Richarz U.
        Predicting long-term response to strong opioids in patients with low back pain: Findings from a randomised controlled trial of transdermal fentanyl and morphine.
        BMC Med. 2007; 5: 39
        • Kehlet H.
        • Dahl J.B.
        The value of “multimodal” or “balanced analgesia” in postoperative pain treatment.
        Anesth Analg. 1993; 77: 1048-1056
        • Komhoff M.
        • Grone H.J.
        • Klein T.
        • Seyberth H.W.
        • Nusing R.M.
        Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function.
        Amer J Physiol. 1997; 272: F460-F468
        • Lanas A.
        • Perez-Asia M.A.
        • Feu F.
        • Ponce J.
        • Saperas E.
        • Santolaria S.
        • Rodrigo L.
        • Balanzo J.
        • Bajador E.
        • Almela P.
        • Navarro J.M.
        • Carballo F.
        • Castro M.
        • Quintero E.
        • and investigators of the Asociación Española de Gastroenterología (AEG)
        A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory use.
        Amer J Gastroenterol. 2005; 100: 1685-1693
        • Lashbrook J.
        • Ossipov M.H.
        • Hunter J.C.
        • Raffa R.B.
        • Tallarida R.J.
        • Porreca F.
        Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1 and COX2-inhibitors in nerve-injured rats.
        Pain. 1999; 82: 65-72
        • Loewe S.
        Die Mischiarnei.
        Klin Wochenschr. 1927; 6: 1077-1085
        • Loewe S.
        Die quantitativen Probleme der Pharmakologie.
        Ergebn Physiol. 1928; 27: 47-187
        • Loewe S.
        The problem of synergism and antagonism of combined drugs.
        Arzneimittelforschung. 1953; 3: 285-290
        • Meier T.
        • Wasner G.
        • Faust M.
        • Kuntzer T.
        • Ochsner F.
        • Hueppe M.
        • Bogousslavsky J.
        • Baron R.
        Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: A randomized, double-blind, placebo-controlled study.
        Pain. 2003; 106: 151-158
        • Miranda H.F.
        • Sierraita F.
        • Pinardi G.
        Neostigmine interactions with nonsteroidal anti-inflammatory drugs.
        Brit J Pharmacol. 2002; 135: 1591-1597
        • Mukherjee D.
        • Nissen S.E.
        • Topol E.J.
        Risk of cardiovascular events associated with selective COX-2 inhibitors.
        JAMA. 2001; 286: 954-959
        • Peloso P.M.
        • Fortin L.
        • Beaulieu A.
        • Kamin M.
        • Rosenthal N.R.
        Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet®) in treatment of chronic low back pain: A multicenter, outpatient, randomized, double-blind, placebo controlled trial.
        J Rheumatol. 2004; 31: 2454-2463
        • Pergolizzi J.
        • Wills L.M.
        Multimodal analgesic therapy.
        in: Shorten G. Carr D.B. Harmon D. Puig M.M. Browne J. Postoperative Pain, an Evidence-based Guide to Practitioners, 1st ed. Saunders Elsevier, Philadelphia, PA2006: 182-196
        • Pert C.B.
        • Snyder S.H.
        Opiate receptor: Demonstration in nervous system.
        Science. 1973; 179: 1011-1014
        • Raffa R.B.
        Pharmacology of oral combination analgesics: Rational therapy for pain.
        J Clin Pharm Ther. 2001; 26: 257-264
        • Raffa R.B.
        Mechanism of action of analgesics used to treat osteoarthritis pain.
        Rheum Dis Clin N Amer. 2003; 29: 733-745
        • Raffa R.B.
        Pharmacological aspects of successful long-term analgesia.
        Clin Rheumatol. 2006; 25: S9-S15
        • Raffa R.B.
        • Friderichs E.
        • Reimann W.
        • Shank R.P.
        • Codd E.E.
        • Vaught J.L.
        • Jacoby H.I.
        • Selve N.
        Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol.
        J Pharmacol Exp Ther. 1993; 267: 331-340
        • Raffa R.B.
        • Stone Jr., D.J.
        • Tallarida R.J.
        Discovery of “self-synergistic” spinal/supraspinal antinociception produced by acetaminophen (paracetamol).
        J Pharmacol Exp Ther. 2000; 295: 291-294
        • Raffa R.B.
        • Stone Jr., D.J.
        • Tallarida R.J.
        Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine.
        Eur J Pharmacol. 2001; 412: R1-R2
        • Raffa R.B.
        • Clark-Vetri R.
        • Tallarida R.J.
        • Wertheimer A.I.
        Combination strategies for pain management.
        Expert Opin Pharmacother. 2003; 4: 1697-1708
        • Rowbotham M.C.
        • Davies P.S.
        • Verkempinck C.
        • Galer B.S.
        Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia.
        Pain. 1996; 65: 39-44
        • Schumacher M.A.
        • Basbaum A.I.
        • Way W.L.
        Opioid analgesics & antagonists.
        in: Katzung B.G. Basic and Clinical Pharmacology. McGraw Hill, New York, NY2007: 489-510
        • Simon E.J.
        • Hiller J.M.
        • Edelman I.
        Stereospecific binding of the potent narcotic analgesic 3H-etorphine to rat brain homogenate.
        Proc Natl Acad Sci USA. 1973; 70: 1947-1949
        • Smalley W.E.
        • Ray W.A.
        • Daugherty J.R.
        • Griffin M.R.
        Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons.
        Amer J Epidemiol. 1995; 141: 539-545
        • Smith H.S.
        Combination opioid analgesics.
        Pain Physician. 2008; 11: 201-214
        • Smith H.S.
        Potential analgesic mechanisms of acetaminophen.
        Pain Physician. 2009; 12: 269-280
        • Smith J.B.
        • Willis A.L.
        Aspirin selectively inhibits prostaglandin production in human platelets.
        Nature. 1971; 231: 235-237
        • Solomon D.H.
        • Schneeweiss S.
        • Levin R.
        • Avorn J.
        Relationship between COX-2 specific inhibitors and hypertension.
        Hypertension. 2004; 44: 140-145
        • Tallarida R.J.
        The Interaction Index: A measure of drug synergism.
        Pain. 2002; 98: 163-168
        • Tallarida R.J.
        Perspectives in Pharmacology: An overview of drug combination analysis with isobolograms.
        J Pharmacol Exp Ther. 2006; 319: 1-7
        • Tallarida R.J.
        Interactions between drugs and occupied receptors.
        Pharmacol Ther. 2007; 113: 197-209
        • Tallarida R.J.
        • Raffa R.B.
        Testing for synergism over a range of fixed ratio drug combinations: Replacing the isobologram.
        Life Sci. 1996; 58: PL23-PL28
        • Tallarida R.J.
        • Stone D.J.
        • McCary J.D.
        • Raffa R.B.
        A response surface analysis of synergism between morphine and clonidine.
        J Pharmacol Exp Ther. 1999; 289: 8-13
        • Tallarida R.J.
        • Cowan A.
        • Raffa R.B.
        Antinociceptive synergy additivity and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice.
        J Pharmacol Exp Ther. 2003; 307: 699-704
        • Terenius L.
        Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane.
        Acta Pharmacol Toxicol. 1973; 32: 317-320
        • Tetzlaff J.E.
        The pharmacology of local anesthetics.
        Anesthesiol Clin N Amer. 2000; 18: 217-233
        • Tzschentke T.M.
        • Christoph T.
        • Kögel B.
        • Schiene K.
        • Hennies H.H.
        • Englberger W.
        • Haurand M.
        • Jahnel U.
        • Cremers T.I.
        • Friderichs E.
        • De Vry J.
        (–)-(1R2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
        J Pharmacol Exp Ther. 2007; 323: 265-276
        • Vane J.R.
        Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.
        Nature. 1971; 231: 232-235
        • Woolf C.J.
        Pain: Moving from symptom control toward mechanism-specific pharmacologic management.
        Ann Intern Med. 2004; 140: 441-451
      5. World Health Organization http://www.who.int/cancer/palliative/painladder/en (last accessed September 24, 2009)